50 Jahre HHU I3 - Interactions, Integrations and

50 Jahre HHU I3 ‐ Interactions, Integrations and Innovations 125 Jahre DPhG DPhG Jahrestagung 2015 Düsseldorf, 23.9. bis 25.9. (22.9. Bürgersymposium + 26.9. Allgemeinpharmazie) Chairman Holger Stark Scientific Organizing Committee Stefan Laufer, Andreas Link, Olaf Queckenberg, Christoph Friedrich, Peter Gmeiner, Jochen Klein, Peter Langguth, Kristina Leuner, Angelika Vollmar, Hermann Wätzig, Thomas Efferth, Ulrike Holzgrabe, Ulrich Jaehde, Heyo Kroemer, Irmgard Merfort, Klaus Mohr, Peter Ruth, Manfred Schubert‐
Zsilavecz, Andrea Sinz, Holger Stark, Dieter Steinhilber, Werner Weitschies, Gerhard Winter Local Organizing Committee Jörg Breitkreuz, Barbara Gioffreda, Holger Gohlke, Alexandra Hamacher, Finn Hansen, Matthias Kassack, Peter Kleinebudde, Thomas Kurz, Stefanie Läer, Claus Passreiter, Peter Proksch, Holger Stark, Aleksandra Zivkovic 1 Version 06, 21.08.2015 50 Jahre HHU I3 ‐ Interactions, Integrations and Innovations 125 Jahre DPhG Dienstag, 22.09.2015
14.00-14.15
14.15-15.00
15.00-15.45
15.45-16.15
16:15-17.00
17.00-17.45
19.00-21.00
20.00-21.00
Bürgersymposium Geschichte der Pharmazie in Düsseldorf:
 Ort: Haus der Universität, Düsseldorf Schadowplatz 14t
Begrüßung durch den Vorsitzenden der FG Geschichte der Pharmazie
Prof. Dr. Christoph Friedrich, Marburg
Zur Entwicklung des Hochschulfaches Pharmazie an der Heinrich-Heine-Universität Düsseldorf
Prof. Dr. Horst Weber, HHU Düsseldorf
Zur Entwicklung des Apothekenwesens in Düsseldorf
Dr. Frederik Vongehr, Mörs
Kaffeepause
Vesters Archiv – eine besondere pharmaziehistorische Quelle aus Düsseldorf im Spannungsfeld privater, städtischer und
universitärer Interessen
Prof. Dr. Frank Leimkugel, HHU Düsseldorf
Zur Geschichte des Düsseldorfer Aqua-Zoos und seines Begründers, Apotheker Theodor Löbbecke (1821–1901)
Sandra Honigs, Aqua-Zoo – Löbbecke-Museum Düsseldorf
Treffen Arbeitsgemeinschaft Katastrophenpharmazie Ort: Haus der Universität, Düsseldorf, Schadowplatz 14
Notfall- und Katastrophenpharmazie - Ein Beitrag der Apotheker zum Bevölkerungsschutz, Daniel Neuser, Düsseldorf-
2 Version 06, 21.08.2015 50 Jahre HHU I3 ‐ Interactions, Integrations and Innovations 125 Jahre DPhG Wednesday, 23.09.2015
Verbands- und Fachgruppen-Meetings
9.00-11.00
11.30-13.00
Sitzung VdPPHI
e.V.
Hochschullehrersit
zung – B. Clement
– (3A)
Fachgruppe
Pharm./Med.
Chemie, P.
Gmeiner (3A)
Fachgruppe Pharm.
Biologie, A. Vollmar
(3D)
Fachgruppe
Pharmakologie, J.
Klein (3E)
Fachgruppe Pharm.
Technologie, P.
Langguth (3B)
Fachgruppe
Klinische
Pharmazie, K.
Friedland (3F)
Fachgruppe
Industriepharmazie
, C. Küster (U1, 23)
Wednesday, 23.09.2015
Main Symposium (Congress language English)
13.00-13.30
Opening of the Annual DPhG Meeting 2015 (3A)
I3 - Interactions, Integration and Innovation
13.30-14.15
14.15-15.00
Plenary lecture 1, Interactions, Integrations and Innovations in Medicinal Chemistry of purinergic signalling,
Christa E. Müller (3A)
Plenary lecture 2, New concepts and products for individual drug dosing Jörg Breitkreuz(3A)
15.00-15.30
Coffee break – Poster viewing (even numbers)
15.30-17.00
SL1 (3A)
Antiviral Drugs
Chairs: H. Rübsamen-Schaeff /
H. Zimmermann
15:30 Thomas Pietschmann: Directly
Short talks, parallel sessions I
SL2 (3D)
Blood/Brain Barrier
Chairs: G. Fricker /F. Helm
15:30 Robin Tremmel: Liposomale delivery
SL3 (3E)
Regulation of beta-cell function –
implications for diabetes
Chairs: G. Drews / E. Oetjen
15:30 Gisela Drews: Role of bile acids in
3 Version 06, 21.08.2015 50 Jahre HHU I3 ‐ Interactions, Integrations and Innovations 125 Jahre DPhG acting antivirals against hepatitis C virus
systems for targeting the blood-brain barrier beta-cell function
– close to “perfectovir”
15:45 Daniela Paulsen: How to deal
with HBV? - State of the art and new 16:00 Stefan Liebner: Molecular regulation
concepts in HBV therapy
of endothelial barrier properties in the
central nervous system
16:00 Christoph Stephan: Advances
and challenges in diagnostics & therapy
for HIV/AIDS
16:15 Helga Rübsamen-Schaeff: The
era after nucleosides: Novel therapeutic
approaches against herpes viruses
16:30 Marise Kolter: Toxicity of poly(nbutylcayan-acrylate) (PBCA) nanoparticles
designed to overcome the blood brain
barrier
16:30 Stephan Ludwig: New avenues
in anti-influenza therapy
15:50 Ingo Rustenbeck: Mobility of
submembrane insulin granules
16:15 Martina Düfer: Reactive oxygen
species: pharmacological target or
physiological prerequisite for beta-cell
function?
16:35 Elke Oetjen: Regulation of betacell function and mass by the dual
leucine zipper kinase
16:45 Johan Neyts: Antivirals, a lot has
been achieved, yet a long way to go
17.00-18.00
Short poster lectures
18.00-22.00
Poster viewing (even numbers) and welcome reception
Thursday, 24.09.2015
8.30-9.15
Plenary lecture 3, Ebola and more: endolysosomal cation channels as novel drug targets, Martin Biel (3A)
9.15-10.00
Plenary lecture 4, The pre-clinical and clinical development of histamine H4 receptor antagonists, Robin Thurmond (3A)
10.00-10.30
Coffee break – Poster viewing (uneven numbers)
4 Version 06, 21.08.2015 50 Jahre HHU I3 ‐ Interactions, Integrations and Innovations 125 Jahre DPhG 10.30-12.00
SL4 (3A)
GLISTEN - GPCR Medicinal
Chemistry
Chairs: N. Tschammer / P. Kolb
Short talks, parallel sessions II
SL5 (3D)
Evidence based Medication Management
Chairs: G. Hempel / S. Läer
10:30Georg Hempel: Introduction
10:30 Francine Acher: Selective
orthosteric agonists in class C GPCRs
11:00 Hans Bräuner-Osborne:
Identification and pharmacological
characterization of endogenous and
surrogate ligands for orphan G proteincoupled receptors
10:35 Thilo Bertsche: Medication
management in clinical care
11:00 Olaf Rose: Management in
ambulatory care: Results of the WestGem
Study
11:30 Sylwia Gawron: Structure free
optimisation of fragments for the β2adrenoreceptor
11:25 Stefan Derix: AMTS activities of the
Pharmacists-Chamber of North Rhine
11:45 Matthias Hillenbrand:
Comprehensive analysis of
heterotrimeric G-protein complex
diversity and their interactions with
GPCRs in solution
11:45 Judith Hildebrand: Comparison of
three lists of Potentially Inadequate
Medications in Old Age (PIMs) in four
German long-term care facilities with
special regard to Adverse Drug Events
(ADEs)
(organized by GLISTEN COST Action
CM1207)
12.00-13.30
SL6 (3E)
(Bio)Analytics
Chairs J. Heilmann / M. Lämmerhofer
10:30 Kai Stühler: Protein mass
spectrometry - Methods and applications
in clinical proteomics
10:50 Gerhard Scriba: Capillary
electrophoresis-based stereospecific
enzyme assay for methionine sulfoxide
reductase
11:10 Shigeru Ohta New Approach for
drug discovery and development:
Prediction of human drug metabolism
using chimeric mice transplanted with
human hepatocytes
11:30 Ryoichi Fujiwara: Importance of
extrahepatic UDP-glucuronosyltransferase
1A1 in bilirubin metabolism
11:45 Maria K. Parr: Renaissance of
supercritical fluid chromatography: Fast
and sensitive analysis of polar drugs and
their metabolites by hyphenated mass
spectrometry
Lunch break – Poster viewing (uneven numbers)
5 Version 06, 21.08.2015 13.30-15.00
50 Jahre HHU I3 ‐ Interactions, Integrations and Innovations 125 Jahre DPhG Short talks, parallel sessions III
SL7 (3A)
SL8 (3D)
SL9 (3E)
Allosteric Regulation
Anti-infective Compounds
Poorly Solubles
Chairs: K. Mohr / M. Bünemann
Chairs: U. Holzgrabe / P. Proksch
Chairs: P. Kleinebudde / W. Weitschies
13:30 Ursula Storch: Molecular
insights into the mechanosensitivity of
histamine H1 receptors
13:30 Tanja Schirmeister: Vinylsulfonebased inhibitors of rhodesain as new antitrypanosomal compounds
13:55 Nuska Tschammer: Biased
signaling and probe dependence at the
chemokine receptor CXCR3
14:00 Christian Klein: Discovery of dengue 14:00 Heike Bunjes: Colloidal carrier
protease inhibitors with nanomolar affinity
systems for the formulation of poorly
water-soluble drugs
14:15 Alexander Titz: The lectin LecB as
target for anti-infectives against chronic
Pseudomonas aeruginosa infections
14:30 Michael Hacker: Oligomeric crosslinkers for hydrogel formulation from ECM14:30 Rainer Kalscheuer: Chlorflavonin
derived macromolecules
inhibits growth of Mycobacterium
tuberculosis by targeting branched-chain
14:45 Dominik Lunter: Contribution of
amino acid biosynthesis
confocal Raman microscopy (CRM) to the
validation of an ex vivo skin penetration
14:45 Georgios Daletos: Marine natural
method
products as potential sources for new
antitubercular agents
14:20 Wiebke Seemann: Muscarinic
M2 receptor allosterism: Contextsensitive signalling
14:45 Susanne Hermans: Detection of
unexplored allosteric pockets using a
“dummy” ligand approach
15.00-15.30
15.30-17.00
13:30 Susanne Page: The use of
screening tools in the development of
amorphous solid dispersions
Coffee break – Poster viewing (uneven numbers)
SL10 (3A)
PPP in Drug Development
Chairs: S. Knapp / F. Bracher
15:30 Stefan Knapp: A Public Private
Short talks, parallel sessions IV
SL11 (3D)
Screening Techniques in Pharmacology
& Drug Development
Chairs: E. Kostenis / H. Wätzig
15:30 Hermann Wätzig: Data quality in
SL12 (3E)
Signaling in cell death
Chairs: I. Merfort / T. Efferth
15:30 Min-Li-Weber: Sensitization of the
6 Version 06, 21.08.2015 50 Jahre HHU I3 ‐ Interactions, Integrations and Innovations 125 Jahre DPhG Partnership for the development of
drug discovery – the role of analytical
anti-cancer efficacy of the Bcl-2 family
chemical tool compounds for the
performance in ligand binding assays
inhibitor ABT-263 by natural compounds
validation of novel targets
15:50 Ramona Schrage: Dynamic Mass
16:00 Beatrice Bachmeier: miR181b is
16:00 Anke Müller-Fahrnow: Public
Redistribution to probe the signaling
induced by the chemopreventive
Private Partnerships in Lead Discovery: repertoire of GPCRs
polyphenol curcumin and inhibits breast
Overview and case study on binding
cancer metastasis via downregulation of
kinetics
16:10 Manuel Grundmann: Label-free
the inflammatory cytokines CXCL1 and 2
biosensors help to reveal a new mechanism
16:20 Conrad Kunick: Development of of GPCR activation
16:30 Qiaoli Zhao: Shikonin and its
a selective DYRK1A inhibitor in a PPP
derivatives inhibit phosphorylation of the
framework
16:20 Michael Koch: Assay technologies
epidermal growth factor receptor signaling
addressing GPCRs in drug discovery
and synergistically kill glioblastoma cells in
16:40 Olaf Kelber: The role of
combination with erlotinib
adenosine in colonic inflammation – A
16:45 Frank Böckler: Semi-automatic
study in rat colon preparations in vitro
fluorescence anisotropy titrations (saFLAT) 16:45 Bertan Bopp: A novel autodisplay
enhance screening throughput and data
based screening assay for the
quality
identification of small molecules that inhibit
the dimerization of human chaperone
Hsp90
17.00-18.30
SL13 (3A)
Anticancer and epigenetic
Drugs
Chairs: M. Kassack/M. Jung
17:00 Daniel Rauh: Targeted
cancer therapies
17:20 Sebastian Wesselborg:
Role of apoptosis signaling in
tumorigenesis and therapy
resistance
Short talks, parallel sessions V
SL14 (3D)
SL15 (3E)
Personalized Medicine –
Focused Pharmaceutical
Biomarker and Diagnostics
Research
Chairs: O. Queckenberg /
Chairs: S. Laufer /D.
T. Dingermann
Steinhilber
17:00 Reinhard Ortmann:
Personalized Medicine: The
challenge to leverage genetic
biomarkers from research level
to routine clinical IVD testing
17:00 Dieter Steinhilber:
Frankfurt Fraunhofer:
Workshop (3B)
T. Hotopp
17:00 Fördermaßnahmen der
DFG - Tipps, Tricks und
Hinweise
17:25 Christa E. Müller: Bonn
/ Neuroallianz:
17:30 Frank Kramer: The
7 Version 06, 21.08.2015 50 Jahre HHU I3 ‐ Interactions, Integrations and Innovations 125 Jahre DPhG Potential of biomarkers to
17:40 Stefan Günther: Novel support decision making in
17:50 Stefan Laufer:
bromodomain inhibitors and
clinical studies in
Tübingen-Stuttgart: ICEPHA
their molecular effects on cell
cardiovascular indications
proliferation in leukemia cells
18:15 General Discussion.
18:00 Stefan Müllner: From
18:00 Christian A. Olsen:
„omics“-technologies to
Using peptide macrocycles to
stratified medicine in
probe the inhibition of histone
autoimmune diseases
deacetylases
18:20 Steffen Lüdeke:
Correlation of conformation
with cytotoxic activity of αaminoxy oligopeptides: A
circular dichroism study
19.30
Conference dinner (Im Goldenen Ring, Burgplatz 21, 40213 Düsseldorf
Friday, 25.09.2015
8.30-9.15
Plenary lecture 5, Liver research in Düsseldorf: Bridging basic and clinical science, Dieter Häussinger(3A)
9.15-10.00
Plenary lecture 6, Drug approval and regulatory science – Where to go? Karl Broich (3A)
10.00-10.30
Coffee break
10.30-12.00
SL16 (3A)
Future molecular design
Chairs: G. Schneider / H. Gohlke
Short talks, parallel sessions VI
SL17 (3D)
Medication safety in special patient
groups
SL18 (3E)
Hot Topics in Pharmaceutical Biology Young Investigators in the Spotlight
8 Version 06, 21.08.2015 50 Jahre HHU I3 ‐ Interactions, Integrations and Innovations 125 Jahre DPhG Chairs: K. Friedland / U. Jaehde
Chairs:S. Alban / A. Vollmar
10:30 Andrew Hopkins: Automated design
of bispecific small molecule drugs
10:30 Stephan Scherneck: Pregnant
and lactating women
11:00 Stephanie Läer: Infants and
11:00 Tina Ritschel: KRIPO-Protein binding children
site similarities for drug design
11:30 Ulrich Jaehde: Elderly patients
11:20 Johannes Kirchmair: Predicting the
in nursing homes
sites and products of drug metabolism
10:30 Kristian Wende: Non-thermal
atmospheric pressure plasma as a
therapeutical option? Molecular Biology as
key for better understanding
10:45 Jandirk Sendker: About the
potential of plant senescence as a new
source for drug discovery
11:00 A. Kristian Apel: Regulation of the
heterologously expressed novobiocin gene
cluster by the host strain Streptomyces
coelicolor M512
11:40 Gisbert Schneider: Enforcing drug
discovery by computational molecular
design
11:15 Sonja Keßler: mRNA binding
proteins in metaflammation and
hepatocarcinogenesis
11:30 Timo Niedermeyer: Cyanobaczeria
in natural product research
11:45 Till Schäberle: Analysis of natural
product – Biosynthesis in the postgenomic era
12.00-13.00
Short Lunch break
13.00-13.45
Plenary lecture 7, From synthetic nucleic acids to artificial genes and genomes: drugs for the future? Piet Herdewijn (3A)
14.00-15.00
Closing ceremony, (3A)
15:15-16:30
DPhG Jahreshauptversammlung (3A)
9 Version 06, 21.08.2015 50 Jahre HHU I3 ‐ Interactions, Integrations and Innovations 125 Jahre DPhG Samstag, 26.09.2015 15.00 Uhr bis 18.30 Uhr Organizing Committee Kathrin Müller, Michael Hannig, Juliane Kresser Tag der Offizinpharmazie (DPhG FG Allgemeinpharmazie, Regionalgruppe Rheinland, LAK) bitte melden Sie sich bzw. Ihre Apotheke zum Tag der Offizinapotheke online an: www.dphg.de/apo15 26.9.2015, Düsseldorf - DPhG-Tag der Offizinpharmazie in Kooperation mit der Deutschen Schmerzgesellschaft (DGS)
Referent:
PD. Dr. med. Michael Überall, Nürnberg, Präsident der Deutschen Schmerzliga e.V.
Ort:
Heinrich-Heine-Universität, Universitätsstr. 1, 40225 Düsseldorf, Hörsaal 3D in Gebäude 23.01
Zeit:
Samstag, den 26.09.2015, 15:00 - 18:30 Uhr
Programm: 1. Teil der Schmerzschulung der DGS Kursart: Vortrag/ TED Fragen (120 Geräte) +Antwortdiskussionen/Fragemöglichkeiten/teilweise = „workshop‐ Charakter“ ( abhängig von der Teilnehmerzahl und Referent) Kosten: Der erste Teil des Kurses ist für alle Teilnehmer (über den Tag der Offizinapotheker) kostenfrei Möglichkeiten für die Teilnehmer: Belegung des 2. Teils des Schmerzkurses zum Erwerb des DGS‐Zertifikats für 190.‐€ (zzgl. MwSt) / pro Apotheke (= 2 Teilnehmer) in den jeweiligen regionalen Kursangeboten Möglichkeit und Kosten der Rezertifizierung: Jährlich: 38 € (zzgl. MwSt.) DPhG‐Mitgliedsapotheken: 28 € (zzgl. MwSt.) Nähere Infos zur Rezertifizierung finden Sie im Internet: http://www.dgschmerzmedizin.de/dgs_campus.html 10 Version 06, 21.08.2015 50 Jahre HHU I3 ‐ Interactions, Integrations and Innovations 125 Jahre DPhG Inhalte – Erster Teil der Schmerzschulung 1. Informationen zur „Deutschen Gesellschaft für Schmerzmedizin“ und der „Deutschen Schmerzliga“ Die Versorgungssituation des Schmerzpatienten in Deutschland, 2. Grundlagen Schmerz (1) Definition (akut vs. chronisch, etc.), Strukturen des nozizeptiven Systems, endogende Schmerzkontrollmechanismen, Pathophysiologie akuter vs. chronischer Schmerzen. 3. Grundlagen Schmerz (2) Epidemiologie, Klassifikation, Schmerz als Symptom vs. Schmerz als Krankheit, bio‐psycho‐soziales Krankheitsmodell, Begleiterscheinungen, Ko‐Morbidität, etc. 4. Differenzialdiagnostik Anamnese/ Diagnostik, Verlauf, Chronifizierungsrisiken, Grundlagen der Prävention und Therapie akuter/chronischer Schmerzen, Schmerzmessung, Selbstauskunfts‐instrumente, etc. 5. Ziele der (medikamentösen) Schmerztherapie Schmerzlinderung, Funktionsverbesserung, Teilhabe an den Aktivitäten des (all)täglichen Lebens, Lebensqualität, individuelle Behandlungsziele, etc. 6. Schmerztherapie – WHO‐Stufe I (Nichtopioide) Paracetamol, Ibuprofen, ASS, Diclofenac, Coxibe, Metamizol, etc.; jeweils mit WM, UAW, KI (Schwerpunkt auf apothekenpflichtige Fertigarzneimittel und Beratungs‐/Verkaufssituation in der Apotheke) 11 Version 06, 21.08.2015